What question did this study set out to answer?

This research aims to evaluate the safety and antitumor activity of lenvatinib combined with pembrolizumab in patients with unresectable hepatocellular carcinoma.

July 27, 2020Journal of Clinical Oncology1,182 citationsOpen Access

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

View Full Paper

RFRichard S. FinnAstraZeneca (United Kingdom)MIMasafumi IkedaNational Cancer Center Hospital East AZAndrew X. ZhuUniversity of Pisa

Key Points

This research aims to evaluate the safety and antitumor activity of lenvatinib combined with pembrolizumab in patients with unresectable hepatocellular carcinoma.
Phase Ib trial design
Combination treatment of lenvatinib and pembrolizumab
Focus on safety and antitumor activity
Combination therapy displayed promising antitumor activity in patients with uHCC
Toxicities observed were manageable and no unexpected safety signals were reported

Abstract

Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC. Toxicities were manageable, with no unexpected safety signals.

Demander à l'IA

Bookmark

View Full Paper

Demander à l'IA

Bookmark

View Full Paper

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Key Points

Abstract

Cite This Study

Also Consider

Also Consider